Company Receives IND Number & Enters FDA Discussion for COPD Clinical Trials

By: Tomas Ronolski - AllPennyStocks.com News

Monday, May 23, 2022

COPD or chronic obstructive pulmonary disease affects breathing, consists of a group of illnesses including emphysema and chronic bronchitis and is the third leading cause of death worldwide. This company is in the process of evaluating stem cells for treatment of this devastating disease.

Biotechnology firm Therapeutic Solutions International (OTCPK:TSOI) has received investigational new drug application number 28508 from the U.S. Food and Drug Administration (FDA) for its proposed clinical study evaluating its adult stem cell product JadiCell for the treatment of COPD.

The firm and the FDA are in negotiations regarding details of the clinical trial and subject population for the product which will be called, “Allogeneic Umbilical Cord Mesenchymal Stem Cells, JadiCell; Intravenous injection”.

Shares were trading down in late morning trade.

Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.